Skip to main content

Table 2 Prevalence of self-reported and urinalysis-screened drug use at among participants (N = 1129)

From: Validity of self-reported substance use: research setting versus primary health care setting

    

Self-reported drug use during the past 12 month

Self-reported drug use during the past 72 h

Positive urinalysis

Self-reported during the past 72 h versus urine testa

drug use

gender

group

N

n (%)

95%CI

p

n (%)

95%CI

P

n (%)

95%CI

p

p

opioid use

Male

RYCS (Research Setting)

494

61 (12.35%)

(9.72–15.57)

0.544

12 (2.43%)

(1.38–4.24)

0.003

32 (6.48)

(4.61–9.03)

0.003

< 0.001

PHC Centers setting

(with urine specimen)

229

32 (13.97%)

(10.03–19.14)

16 (6.99%)

(4.31–11.14)

 

30 (13.10)

(9.29–18.16)

< 0.001

PHC Centers setting

(total)

270

39(14.44)

(10.71–19.20)

0.412

19 (7.04)

(4.52–10.80)

0.002

–

–

–

–

Female

RYCS (Research Setting)

113

6 (5.31%)

(2.38–11.44)

0.039

1 (0.88)

(0.12–6.18)

0.767

1 (0.88)

(0.12–6.18)

0.362

1.00

PHC Centers setting

(with urine specimen)

171

2 (1.17%)

(0.29–4.62)

1 (0.58)

(0.081–4.11)

 

4 (2.34)

(0.87–6.12)

0.250

PHC Centers setting

(total)

252

3 (1.19)

(0.38–3.04)

0.019

2 (0.79)

(0.20–3.15)

0.929

–

–

–

–

total

RYCS (Research Setting)

607

67(11.04)

(8.77–13.80)

0.190

13(2.14)

(1.25–3. 66)

0.054

33(5.44)

(3.89–7.56)

0.056

< 0.001

PHC Centers setting

(with urine specimen)

400

34(8.50)

(6.13–11.68)

17 (4.25)

(2.65–6.74)

 

34 (8.50)

(6.13–11.68)

< 0.001

PHC Centers setting

(total)

522

42 (8.05)

(5.99–10.72)

0.090

21 (4.02)

(2.63–6.10)

0.065

–

–

–

–

cannabis

Male

RYCS (Research Setting)

494

8 (1.62%)

(0.81–3.21)

0.595

1 (0.20%)

(0.028–1.4)

0.192

10 (2.02)

(1.09–3.73)

0.001

0.004

PHC Centers setting

(with urine specimen)

229

5 (2.18%)

(0.71–5.02)

2 (0.87%)

(0.22–3.5)

 

16 (6.99)

(4.05–11.10)

< 0.001

PHC Centers setting

(total)

270

5 (1.85%)

(0.60–4.3)

0.812

2 (0.74)

(0.09–2.65)

0.255

–

–

–

–

methadone

Male

RYCS (Research Setting)

494

16 (3.24%)

(1.99–5.23)

0.302

4 (0.81%)

(0.30–2.14)

0.053

19 (3.85)

(2.46–5.96)

0.000

< 0.001

PHC Centers setting

(with urine specimen)

229

11 (4.80%)

(2.68–8.50)

6 (2.62%)

(1.17–5.74)

 

25 (10.92)

(7.46–15.70)

< 0.001

PHC Centers setting

(total)

270

12(4.44)

(2.53–7.69)

0.397

6(2.22)

(1–4.88)

0.101

–

–

–

–

female

RYCS (Research Setting)

113

0 (0%)

0 (0%)

–

0 (0%)

0 (0%)

–

1 (0.88)

 

0.362

1.00

PHC Centers setting

(with urine specimen)

171

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 

4 (2.34)

 

0.125

PHC Centers setting

(total)

252

0 (0%)

0 (0%)

–

0 (0%)

0 (0%)

–

–

–

–

–

total

RYCS (Research Setting)

607

16 (2.64)

(1.51–4.25)

0.913

4 (0.66)

(0.18–1.68)

0.188

20(3.29)

(2.02–5.04)

0.004

< 0.001

PHC Centers setting

(with urine specimen)

400

11 (2.75)

(1.38–4.87)

6 (1.50)

(0.55–3.24)

 

29 (7.25)

(4.91–10.25)

< 0.001

PHC Centers setting

(total)

522

12 (2.30)

(1.19–3.98)

0.717

6 (1.15)

(0.42–2.48)

0.381

–

–

–

–

amphetamine and Methamphetamine

Male

RYCS (Research Setting)

494

0

0

 

0

0

 

1 (0.20)

(0.03–1.33)

0.557

1.00

PHC Centers setting

(with urine specimen)

229

0

0

0

0

 

2 (0.87)

(0.11–3.12)

0.50

PHC Centers setting

(total)

270

1

0.37

0.176

1

0.37

0.176

–

–

–

–

  1. a The results of standard tests (urine test) were compared with the results of Self-reporting of substance use during the past 72 h by McNamara’s test